The U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application (ANDA) numbered 076346 submitted by Teva Pharmaceuticals USA, Inc. for the loop diuretic torsemide.
The approved product is an oral tablet marketed under the brand name TORSEMIDE, available in four strengths – 5 mg, 10 mg, 20 mg, and 100 mg – each designated as prescription‑only.
The submission history includes an original filing on 30 May 2003, subsequent manufacturing (CMC) and labeling supplements, with the most recent labeling supplement submitted on 4 May 2020.
FDA labeling classifies torsemide as a loop diuretic that increases diuresis at the loop of Henle.
Cập nhật pháp chế26 thg 8, 2026•1 phút đọc
FDA Approves Teva Torsemide Generic Tablets (ANDA 076346)
The FDA has approved Teva Pharmaceuticals’ ANDA 076346 for torsemide oral tablets in 5 mg, 10 mg, 20 mg and 100 mg strengths, prescription‑only.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá